More Downside in Merck?Merck has been sliding for more than a year. Now, following a period of consolidation, some traders may see further downside risk.
The first pattern on today’s chart is the range between the August 26 high of $85.59 and the August 28 close of $83.21, where the pharmaceutical giant spent almost thre
Key facts today
Merck & Co. announced the cancellation of its research operations in London, citing challenges in the UK's pharmaceutical investment environment.
Berenberg has reduced its price target for Merck & Co. (MRK) from $100.00 per share to $90.00 per share.
1,350 ARS
15.67 T ARS
58.58 T ARS
About Merck & Company, Inc.
Sector
Industry
CEO
Robert M. Davis
Website
Headquarters
Rahway
Founded
1891
ISIN
ARDEUT110277
FIGI
BBG000FSRB61
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Related stocks
MRK is showing some breakout signsThe white fork is pointing slightly to the upside.
CIB is broken and signals a change in behavior. The pullback to it was very nice - a Eye twinkle? §8-)
Then price opened the door to the upside by peeking through the resistance of the consolidation, asking: "Anybody here to buy me?"...silence...
double top includes a solid major high as second top=SELL1->3 : we create a double top with the area above 1 and 3 being a
pressure zone pushing price down
2: this is the low created when sellers entered the first time
4: the is the low created when sellers entered the second time
3 : due to the fact that the sellers that originated from 3 created
Is Merck Ready for a Rebound?Fundamental Analysis
Financial Performance
Revenue Decline: Q2 revenue fell 2% year-over-year to $15.8 billion.
Earnings Drop: Adjusted earnings per share decreased by 7% to $2.13.
Key Product Challenges
Keytruda Competition: Facing increased competition for its top cancer drug, Keyt
Can Global Chaos Fuel Pharmaceutical Giants?Merck's remarkable growth trajectory demonstrates how a pharmaceutical leader can transform global uncertainties into strategic advantages. The company has masterfully navigated geopolitical tensions, including US-China trade disputes, by diversifying supply chains and establishing regionalized manu
MRK potentially enters the Wyckoff accumulation phase this week.The weekly chart points strongly towards a stock emerging from a prolonged Markdown Phase and potentially entering Accumulation (Phase C), with signs of strength appearing.
Merck is basically yelling 'buy me' across all timeframes, so I'm jumping into a long call
MRK - Retesting BreakoutAfter being in a downtrend for almost a year things finally look like they are starting to turn around for MRK.
Recently price broke the downwards sloping resistance and has retested that level as a new support level. We have also seen strength increasing on our daily RSI bringing some life back i
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
MRK5584756
Merck & Co., Inc. 5.15% 17-MAY-2063Yield to maturity
5.43%
Maturity date
May 17, 2063
MRK6166087
Merck & Co., Inc. 5.7% 15-SEP-2055Yield to maturity
5.38%
Maturity date
Sep 15, 2055
MRK5319197
Merck & Co., Inc. 2.9% 10-DEC-2061Yield to maturity
5.36%
Maturity date
Dec 10, 2061
MRK5584755
Merck & Co., Inc. 5.0% 17-MAY-2053Yield to maturity
5.32%
Maturity date
May 17, 2053
MRK4806294
Merck & Co., Inc. 4.0% 07-MAR-2049Yield to maturity
5.31%
Maturity date
Mar 7, 2049
US58933YBF1
Merck & Co., Inc. 2.75% 10-DEC-2051Yield to maturity
5.30%
Maturity date
Dec 10, 2051
MRK5002693
Merck & Co., Inc. 2.45% 24-JUN-2050Yield to maturity
5.30%
Maturity date
Jun 24, 2050
US58933YAT2
Merck & Co., Inc. 3.7% 10-FEB-2045Yield to maturity
5.26%
Maturity date
Feb 10, 2045
MRK5584925
Merck & Co., Inc. 4.9% 17-MAY-2044Yield to maturity
5.23%
Maturity date
May 17, 2044
US58933YAJ4
Merck & Co., Inc. 4.15% 18-MAY-2043Yield to maturity
5.21%
Maturity date
May 18, 2043
MRK3900816
Merck & Co., Inc. 3.6% 15-SEP-2042Yield to maturity
5.16%
Maturity date
Sep 15, 2042
See all MRK bonds